Creativity and vision you need critical thinking included

Innovation Record

Importantly marketing management has relied on Dr. Riker’s vision and technical assessment for many breakthrough innovations including naproxen (Aleve®) and omeprazole (Prilosec OTC®) switches. Moreover, the recent emergence of TENS devices as a new segment of the OTC analgesic category originated with his 2005 vision that TENS devices ought to be available to consumers and directly led to the leading branded launches in the retail channel.  The question for today’s market is: “What lies beyond line extensions in a world with so few switches?

  • Wrote technical recommendation to acquire and switch naproxen OTC as the second NSAID to market (Richardson-Vicks soon acquires from Syntex; later branded Aleve, then sold to Bayer).
  • Oversaw the installation of the first in-house colds virology and clinical sedation testing facility installed within any OTC drug division (Richardson-Vicks/P&G); managed all common cold and allergy key opinion leaders and clinical trials. Proprietary data used to guide technology development and acquisition decisions.
  • Oversaw a 4-year in-house study of common cold symptoms leading to the publication of data supporting the rational use of multisymptom relief products in colds (Richardson-Vicks/P&G).
  • As Associate Director at Richardson-Vicks/P&G, prior to any category switch, managed all clinical evaluation of NSAIDS, non-sedating antihistamines, intranasal steroids and interferon as potential Rx switch opportunities in allergy and the common cold.
  • In a landmark New England Journal of Medicine article demonstrated that average common colds result in significant objective sinus involvement allowing support of multisymptom relief product claims.
  • At P&G wrote and presented technical recommendation for first-in-category OTC switch of an Rx PPI, omeprazole, to senior corporate management (P&G then acquires from Astra; soon branded as Prilosec; first PPI to launch in the mass market).
  • As Chattem’s VP R&D & CSO rebuilt R&D and product development organizations to allow line extensions, acquisition of J&J brands, inherent Rx switch capability, and invention/extension of the Gold Bond Ultimate line.
  • The seminal visionary behind the emergence of TENS devices as an incremental segment within the OTC analgesic category.
    • Urged Chattem senior management to develop a TENS device for the OTC market [2004]. Chattem develops Icy Hot Smart Relief as the first branded TENS device to enter the mass analgesic market.
    • Co-founder, co-inventor and investor in Modular Therapeutx, LLC, a 2009 self-funded start-up devoted to bringing to the mass market an integrated, wireless and patented TENS unit to relieve low back pain (global rights licensed to Hollywog, LLC; Hollywog later sublicenses US retail channel rights to a major OTC analgesic brand; launched in mid-2016).
    • Co-inventor of US patent 9,764,133 [granted 9/19/17] claiming the configuration of integrated portable TENS devices controlled remotely by means of a wireless signal in order to allow for wireless activation and control of the device.

© 2015-2016, On Point Advisors, Inc. | Website by 7 Weight Designs | Privacy Policy